In contrast, the recent PROMINENT (Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes) trial showed no benefits for ASCVD prevention in individuals with mild to moderate hypertriglyceridemia and type 2 diabetes of lowering triglyceride, RLP-C, and apoCIII levels by pemafibrate, which also raised LDL-C levels45 and did not change small dense LDL-C levels.46 Here, APOC3 is linked to hypertriglyceridemia.